J L Harousseau

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution

Éolia Brissot, Fanny Rialland, Xavier Cahu, Marion Strullu et autres

fr, au (code pays fourni par la source)

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

Bilal Mohty, Ibrahim Yakoub‐Agha, Philippe Moreau, J L Harousseau et autres

In multiple myeloma, peripheral neuropathy has for a long time been considered as mainly secondary to the plasma cell dyscrasia itself. With the advent of new targeted drugs such as thalidomide and bortezomib, the iatrogenic neurotoxicity has become the leading cause of …

ch, fr, us, nl (code pays fourni par la source)

Factors Predicting Allogeneic Peripheral Blood Stem Cell (PBSC) Mobilization After G-CSF Treatment in Healthy Donors

Éolia Brissot, P. Chevallier, Thierry Guillaume, J. Delaunay et autres

Some healthy donors may show poor mobilization response to G-CSF and poor CD34+ apheresis yields. Therefore, identifying donors at risk for poor mobilization could be of value in optimising transplantation approaches. This single centre report analyzed factors associated with PBSC mobilization and …

fr (code pays fourni par la source)

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group

H. Zwierzina, Stefan Suciu, R Neuwírtová, Pierre Fenaux et autres

at, be, cz, fr, de, nl, it (code pays fourni par la source)

Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours

Ugo De Giorgi, Giovanni Rosti, S Slavin, Isaac Yaniv et autres

We reviewed the European Group for Blood and Marrow Transplantation (EBMT) experience with salvage high-dose chemotherapy (HDC) in paediatric patients with extragonadal germ-cell tumour (GCT). A total of 23 children with extragonadal GCT, median age 12 years (range 1-20), were treated with …

it, il, fr, at, tr (code pays fourni par la source)

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease

Florence Magrangeas, Valéry Nasser, Hervé Avet‐Loiseau, Béatrice Loriod et autres

Although multiple myeloma (MM) is a unique entity, a marked heterogeneity is actually observed among the patients, which has been first related to immunoglobulin (Ig) types and light chain subtypes and more recently to chromosomal abnormalities. To further investigate this genetic heterogeneity, …

fr (code pays fourni par la source)

Interferon α extends the survival of human myeloma cells through an upregulation of the Mcl‐1 anti‐apoptotic molecule

Denis Puthier, Wilfrid Thabard, Marie‐José Rapp, Marguerite Etrillard et autres

We have recently reported that Mcl-1, an anti-apoptotic member of the Bcl-2 family, is upregulated by interleukin (IL)-6 in human myeloma cells through the janus kinase/signal transducers and activators of transduction (JAK/STAT) pathway. In the current study, we have explored the effects …

fr (code pays fourni par la source)

High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol

Pauline Brice, D. Simon, Réda Bouabdallah, Coralie Bélanger et autres

fr, be, ch (code pays fourni par la source)

Itraconazole Oral Solution for Primary Prophylaxis of Fungal Infections in Patients with Hematological Malignancy and Profound Neutropenia: a Randomized, Double-Blind, Double-Placebo, Multicenter Trial Comparing Itraconazole and Amphotericin B

J L Harousseau, A. W. Dekker, Aspasia Stamatoullas‐Bastard, Αthanasios Fassas et autres

Systemic and superficial fungal infections are a major problem among immunocompromised patients with hematological malignancy. A double-blind, double-placebo, randomized, multicenter trial was performed to compare the efficacy and safety of itraconazole oral solution (2.5 mg/kg of body weight twice a day) with …

ca, fr, gr, at, pt, be, es (code pays fourni par la source)

Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral Environment

Sophie Derenne, Martine Amiot, Sophie Barillé‐Nion, M. Collette et autres

Bisphosphonates have recently been introduced in the therapeutic armamentarium for the long-term treatment of patients with multiple myeloma (MM). These pyrophosphate analogs not only reduce the occurrence of skeletal-related events but also provide patients with a clinical benefit and improve the survival …

fr (code pays fourni par la source)

[Leukemias induced by anticancer chemotherapies].

J L Harousseau

The frequency of leukemia and myelodysplasia following treatment with cytotoxic agents is increasing. Theses treatment-related leukemias raise both theoretical and practical concerns. On a theoretical basis, cytogenetic and molecular abnormalities described constitute useful models to study leukemogenesis. On a practical basis, prognosis …

ca, fr (code pays fourni par la source)

[High-dose melphalan in patients with multiple myeloma].

Philippe Moreau, M. Le Bonniec, J L Harousseau

Since 1983 an increasing number of clinical trials have used high-dose melphalan with or without autologous stem cell support in patients with multiple myeloma. It has been shown that high-dose therapy including high-dose melphalan may be considered as the treatment of choice …

ca, fr (code pays fourni par la source)